Masimo (MASI) to Release Earnings on Tuesday

Masimo (NASDAQ:MASI - Get Free Report) is expected to issue its Q1 2025 quarterly earnings data after the market closes on Tuesday, May 6th. Analysts expect Masimo to post earnings of $1.24 per share and revenue of $367.79 million for the quarter.

Masimo (NASDAQ:MASI - Get Free Report) last announced its earnings results on Tuesday, February 25th. The medical equipment provider reported $1.80 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.42 by $0.38. The company had revenue of $600.70 million for the quarter, compared to analysts' expectations of $593.35 million. Masimo had a net margin of 3.85% and a return on equity of 14.98%. On average, analysts expect Masimo to post $4 EPS for the current fiscal year and $5 EPS for the next fiscal year.

Masimo Price Performance

Shares of NASDAQ:MASI traded up $2.77 during midday trading on Friday, hitting $166.42. The company's stock had a trading volume of 511,618 shares, compared to its average volume of 662,613. The company has a market cap of $8.99 billion, a P/E ratio of 114.77 and a beta of 1.28. Masimo has a 12-month low of $101.61 and a 12-month high of $194.88. The business's 50 day simple moving average is $164.80 and its 200 day simple moving average is $165.98. The company has a debt-to-equity ratio of 0.50, a quick ratio of 1.11 and a current ratio of 2.01.

Analyst Ratings Changes

A number of equities research analysts have recently issued reports on the company. Wells Fargo & Company upped their price target on Masimo from $193.00 to $205.00 and gave the company an "overweight" rating in a research report on Wednesday, February 26th. Needham & Company LLC restated a "hold" rating on shares of Masimo in a report on Thursday, April 10th. Finally, Piper Sandler lifted their price target on Masimo from $210.00 to $215.00 and gave the stock an "overweight" rating in a report on Wednesday, February 26th. One analyst has rated the stock with a hold rating and five have assigned a buy rating to the company. According to data from MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus price target of $194.80.

Insiders Place Their Bets

In other Masimo news, COO Bilal Muhsin sold 30,000 shares of the stock in a transaction dated Monday, March 10th. The shares were sold at an average price of $167.49, for a total transaction of $5,024,700.00. Following the completion of the transaction, the chief operating officer now owns 24,172 shares of the company's stock, valued at $4,048,568.28. This trade represents a 55.38 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director Craig B. Reynolds sold 2,053 shares of the business's stock in a transaction that occurred on Friday, March 14th. The shares were sold at an average price of $166.13, for a total transaction of $341,064.89. Following the completion of the sale, the director now directly owns 16,581 shares in the company, valued at $2,754,601.53. This trade represents a 11.02 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 9.70% of the stock is owned by insiders.

About Masimo

Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and regional oximetry.